Want to see SNN full AI Analyst Report?
SNN Stock Chart & Stats
$32.96
-$0.18(-0.73%)
At close: 4:00 PM EST
$32.96
-$0.18(-0.73%)
Day’s Range― - ―
52-Week Range$28.56 - $38.79
Previous CloseN/A
Volume262.39K
Average Volume (3M)482.36K
Market Cap
$12.82B
Enterprise Value$15.53B
Total Cash (Recent Filing)$557.00M
Total Debt (Recent Filing)$3.33B
Price to Earnings (P/E)20.8
Beta0.51
Next Earnings
Aug 04, 2026EPS Estimate
0.94Next Dividend Ex-DateN/A
Dividend Yield2.28%
Share Statistics
EPS (TTM)1.46
Shares Outstanding421,722,080
10 Day Avg. Volume593,629
30 Day Avg. Volume482,356
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)2.69
Price to Sales (P/S)2.30
P/FCF Ratio16.65
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda9.83
Forecast
1Y Price Target
$32.32Price Target Upside-1.94% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.21
Revenue Forecast (FY)$6.57B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSmith & Nephew has materially improved cash generation: operating cash flow rose to $1.29B and free cash flow to $854M in 2025. Durable FCF supports reinvestment, share buybacks, dividends, and M&A discipline over the medium term and underpins the company's ability to fund RISE strategy and delever over time.
Margin RecoveryMargin expansion reflects sustainable operational improvements: enterprise cost savings, manufacturing optimisation and productivity lifted trading margin and net margin in 2025. Higher margins improve ROIC and resilience to cyclical headwinds, supporting durable profitability and capacity to invest in innovation and commercial scale.
Innovation-led GrowthA high share of growth from recent launches plus record CORI robotic placements indicates durable product-cycle momentum. Continued new product introductions, robotics adoption and platform rollouts increase procedure share, recurring consumable demand, and structural upside from shifts to ASCs and minimally invasive surgery over the medium term.
Bears Say
U.S. Reimbursement RiskRegulatory reimbursement changes directly reduce pricing and volumes for a key wound care subcategory, creating a structural margin and revenue headwind. Even if partly offset by cost savings, sustained lower reimbursement compresses returns on that portfolio and forces commercial and product strategy adjustments.
China VBP PressureVolume‑based procurement in China has materially reduced pricing and sales, shrinking a previously meaningful market presence. Such procurement reforms tend to be persistent and can limit growth and margin recovery in Greater China, requiring prolonged commercial repositioning or product repricing to restore returns.
Portfolio Rationalization & RestructuringLarge one‑off rationalisation indicates meaningful SKU and manufacturing changes that reduce complexity but create execution risk and near‑term cash and margin strain. Transition costs and inventory write‑downs can depress reported profitability and challenge service levels while changes are embedded, affecting medium‑term growth pacing.
SNN FAQ
What was Smith & Nephew Snats’s price range in the past 12 months?
Smith & Nephew Snats lowest stock price was $28.55 and its highest was $38.79 in the past 12 months.
What is Smith & Nephew Snats’s market cap?
Smith & Nephew Snats’s market cap is $12.82B.
When is Smith & Nephew Snats’s upcoming earnings report date?
Smith & Nephew Snats’s upcoming earnings report date is Aug 04, 2026 which is in 21 days.
How were Smith & Nephew Snats’s earnings last quarter?
Smith & Nephew Snats released its earnings results on Mar 02, 2026. The company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.155 by $0.025.
Is Smith & Nephew Snats overvalued?
According to Wall Street analysts Smith & Nephew Snats’s price is currently Overvalued.
Does Smith & Nephew Snats pay dividends?
Smith & Nephew Snats pays a Semiannually dividend of $0.482 which represents an annual dividend yield of 2.28%. See more information on Smith & Nephew Snats dividends here
What is Smith & Nephew Snats’s EPS estimate?
Smith & Nephew Snats’s EPS estimate is 0.94.
How many shares outstanding does Smith & Nephew Snats have?
Smith & Nephew Snats has 421,722,080 shares outstanding.
What happened to Smith & Nephew Snats’s price movement after its last earnings report?
Smith & Nephew Snats reported an EPS of $1.18 in its last earnings report, beating expectations of $1.155. Following the earnings report the stock price went down -3.088%.
Which hedge fund is a major shareholder of Smith & Nephew Snats?
Currently, no hedge funds are holding shares in SNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Snats Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.32 (-1.94% Downside)
$32.32 (-1.94% Downside)
Blogger Sentiment
Bullish
SNN Sentiment 67%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 418.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.53%
12-Months-Change
Fundamentals
Return on Equity
11.79%
Trailing 12-Months
Asset Growth
0.99%
Trailing 12-Months
Company Description
Smith & Nephew Snats
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
SNN Stock 12 Month Forecast
Average Price Target
$32.32
▼(-1.94% Downside)
Technical Analysis
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
0.31% Mutual Funds
0.05% Other Institutional Investors
99.38% Public Companies and
Individual Investors









